Smith Group Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Smith Group Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-22,800	Closed	-$99K	–	524
2016 Q1	$99K	Sell	22,800 -129,670	-85%	-$577K	﹤0.01%	275
2015 Q4	$935K	Sell	152,470 -3,590	-2%	-$23.5K	0.03%	175
2015 Q3	$893K	Buy	+156,060	New	+$1.2M	0.03%	169
2013 Q4	–	Sell	-183,820	Closed	-$923K	–	449
2013 Q3	$923K	Sell	183,820 -19,000	-9%	-$103K	0.04%	181
2013 Q2	$905K	Buy	+202,820	New	+$910K	0.04%	185

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Smith Group Asset Management's PGNX Position: Q2 2016 in Review

Smith Group Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2016, closing a stake of 22,800 shares — an estimated $99K sold.

Smith Group Asset Management first reported a position in PGNX in Q2 2013 and held it in 5 quarters. The position peaked at $935K in Q4 2015. 104 funds tracked by Wall St. Rank hold PGNX as of Q2 2016.

Smith Group Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
Smith Group Asset Management sold 22,800 Progenics Pharmaceuticals Inc shares in Q2 2016, an estimated $99K.
Smith Group Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 5 quarters.
Smith Group Asset Management's Progenics Pharmaceuticals Inc position peaked at $935K in Q4 2015.
104 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2016.

Based on Smith Group Asset Management's 13F filing for Q2 2016, filed 26 Jul 2016.